Allo-aca
PRODUCTS SPECIFICATIONS
DESCRIPTION
Overview
| MDL | - |
|---|---|
| Molecular Weight | 1074.19 |
| Molecular Formula | C48H75N13O15 |
| SMILES | - |
Summary
In Vitro
Allo-aca inhibits leptin-induced proliferation of MDA-MB-231 cells at 50 pM concentration. Allo-aca inhibits leptin-induced proliferation of MCF-7 cells with an IC
50
of 200 pM
[1]
.
Allo-aca at 250 nmol/L reduces VEGF-dependent leptin mRNA expression in both cell lines below base levels. Allo-aca inhibits VEGF mitogenic effects. Allo-aca inhibits VEGF-induced chemotaxis and chemokinesis in RF/6A retinal endothelial cells
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
In an MDA-MB-231 orthotopic mouse xenograft model, Allo-aca administered subcutaneously significantly extends the average survival time from 15.4 days (untreated controls) to 24 and 28.1 days at 0.1 and 1mg/kg/day doses, respectively [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Sealed storage, away from moisture
| Powder | -80°C | 2 years |
|---|---|---|
| -20°C | 1 year |
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H 2 O : 50 mg/mL ( 46.55 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 0.9309 mL | 4.6547 mL | 9.3093 mL |
| 5 mM | 0.1862 mL | 0.9309 mL | 1.8619 mL |
| 10 mM | 0.0931 mL | 0.4655 mL | 0.9309 mL |
References
- [1] Otvos L Jr, et al. Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. Eur J Cancer. 2011;47(10):1578-1584.
- [2] Coroniti R, et al. Designer Leptin Receptor Antagonist Allo-aca Inhibits VEGF Effects in Ophthalmic Neoangiogenesis Models [published correction appears in Front Mol Biosci. 2016 Nov 18;3:75]. Front Mol Biosci. 2016;3:67. Published 2016 Oct 13.